Interventions in clinical acute renal failure: what are the data?

Area of Science:

• Nephrology
• Critical Care Medicine
• Pharmacology

Background:

• Acute renal failure (ARF) presents diverse etiologies and clinical settings, complicating treatment efficacy assessment.
• Limited rigorous studies hinder understanding of interventions for ARF, a condition with high mortality.
• Varied endpoints and comorbid factors further challenge the evaluation of ARF treatments.

Purpose of the Study:

• To analyze existing literature, focusing on controlled studies, to identify effective prophylactic and therapeutic interventions for ARF.
• To evaluate the impact of pharmacologic agents, dialysis modes, and nutritional regimens on ARF outcomes.
• To provide insights into interventions most likely to benefit patients in specific ARF contexts.

Main Methods:

• Systematic review of controlled studies on ARF interventions.
• Analysis of pharmacologic agents using renal function, azotemia course, and mortality as endpoints.
• Evaluation of dialysis and nutritional therapies based on azotemia, nitrogen balance, and mortality.

Main Results:

• Mannitol demonstrates prophylactic efficacy in kidney transplantation; diuretics show no significant benefit in ARF.
• Vasoactive agents like diltiazem (prophylaxis) and dopamine (early ARF) have limited supporting data; atrial natriuretic peptide and calcium channel blockers may aid established ARF.
• Biocompatible membranes show efficacy in ARF recovery and survival; nutritional therapy benefits from amino acid supplementation.

Conclusions:

• Few pharmacologic agents offer proven benefits for ARF prophylaxis or treatment.
• Biocompatible membranes represent a significant advancement in ARF management.
• Nutritional support, particularly amino acid supplementation, is advisable in ARF management.